Pulmonology
Lung Cancer
More in Lung Cancer
EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy
Actual rates for 2021 lagged behind projections
Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan
However, plinabulin plus docetaxel still "not ready for prime time," expert says
Absolute improvement of almost 30%, doubling of duration of response with savolitinib
Two-trial analysis shows about a 40% decreased risk of disease recurrence or death
Novel agent nearly halved risk of progression as first-line therapy in phase III trial
Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy
In Japanese trial, nivolumab-ipilimumab didn't improve OS versus pembrolizumab, had more toxicity
Alternate criteria based on years of smoking has higher sensitivity and specificity, study says
Lazertinib plus amivantamab improved PFS by about 7 months versus single-agent osimertinib
More data for discussion of controversial association between steroids, immunotherapy
PD-L1 checkpoint inhibitor approved for use in NSCLC before and after surgery
Colorectal cancer screening accounted for 64% of the total amount
